J.C. Hsu
Post Doctoral Fellow
postdoc
Internal Med, College of Medicine
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
J.C. Hsu's research focuses on understanding and preventing cardiotoxicity induced by the chemotherapy drug doxorubicin. Their work investigates the role of dexrazoxane, an iron chelator, in mitigating this adverse effect. Specifically, Hsu has studied the dose-response and time course of dexrazoxane's action, examining how it leads to the degradation of topoisomerase 2b, an enzyme implicated in doxorubicin-induced heart damage. This research aims to refine treatment strategies to protect patients from the long-term cardiovascular consequences of cancer therapy. Hsu collaborates with Edward T.H. Yeh and Hui‐M. Chang at the University of Arkansas for Medical Sciences. Their scholarly contributions include 11 publications with 32 citations and an h-index of 3. Hsu's most recent publication is from 2025, indicating ongoing activity in the field.
Metrics
- h-index: 3
- Publications: 11
- Citations: 33
Selected Publications
-
Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b (2025)
-
Abstract 12348: Targeted Degradation of Topoisomerase 2b by Dexrazoxane for Prevention of Doxorubicin-Induced Cardiotoxicity: Dose and Time Course Study in Human (2023)
Collaboration Network
Top Collaborators
- Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b
- Abstract 12348: Targeted Degradation of Topoisomerase 2b by Dexrazoxane for Prevention of Doxorubicin-Induced Cardiotoxicity: Dose and Time Course Study in Human
- Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b
- Abstract 12348: Targeted Degradation of Topoisomerase 2b by Dexrazoxane for Prevention of Doxorubicin-Induced Cardiotoxicity: Dose and Time Course Study in Human
- Abstract 12348: Targeted Degradation of Topoisomerase 2b by Dexrazoxane for Prevention of Doxorubicin-Induced Cardiotoxicity: Dose and Time Course Study in Human
- Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b
Similar Researchers
Based on overlapping research topics